[go: up one dir, main page]

CY1108114T1 - Μεθοδοι για την παρασκευη φαρμακευτικων συνθεσεων που περιεχουν αναλογα εποθειλονης για την θεραπευτικη αγωγη του καρκινου - Google Patents

Μεθοδοι για την παρασκευη φαρμακευτικων συνθεσεων που περιεχουν αναλογα εποθειλονης για την θεραπευτικη αγωγη του καρκινου

Info

Publication number
CY1108114T1
CY1108114T1 CY20081100590T CY081100590T CY1108114T1 CY 1108114 T1 CY1108114 T1 CY 1108114T1 CY 20081100590 T CY20081100590 T CY 20081100590T CY 081100590 T CY081100590 T CY 081100590T CY 1108114 T1 CY1108114 T1 CY 1108114T1
Authority
CY
Cyprus
Prior art keywords
preparation
diluent
methods
pharmaceutical compositions
compositions containing
Prior art date
Application number
CY20081100590T
Other languages
English (en)
Inventor
Rebanta Bandyopadhyay
Timothy M Malloy
Andrea Panaggio
Krishnaswamy Srinivas Raghavan
Sailesh Amilal Varia
Usa
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28678063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108114(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1108114T1 publication Critical patent/CY1108114T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Αποκαλύπτεται μία μέθοδος για τον σχηματισμό παρασκευάσματος κάποιων αναλόγων εποθειλόνης (epothilone) για παρεντερική χορήγηση όπου το ανάλογο διαλύεται σε ένα μίγμα από τουλάχιστον 50% κατ' όγκο τριτ-βουτανόλης σε νερό, το μίγμα λυοφιλοποιείται, το προκύπτον λυοφιλιποιημένο προϊόν συσκευάζεται σε ένα φιαλίδιο ενώ μία επαρκούσα ποσότητα διαλύτη που περιλαμβάνει άνυδρη αιθανόλη και ένα κατάλληλο μη-ιοντικό επιφανειακούς δραστικό μέσον συσκευάζεται σε ένα δεύτερο φιαλίδιο. Όλες οι βαθμίδες διεξάγονται υπό προστασία από το φως. Κατά την χρήση, τα περιεχόμενα του δευτέρου φιαλιδίου ή ο διαλύτης αραίωσης προστίθενται στο λυοφιλοποιημένο προϊόν και αναμιγνύονται για να επανρευστοποιηθεί το ανάλογο εποθειλόνης και το προκύπτον διάλυμα αραιώνεται με ένα κατάλληλο αραιωτικό μέσον για να παραχθεί ένα διάλυμα για ενδοφλέβια έγχυση που περιέχει το ανάλογο εποθειλόνης σε μία συγκέντρωση από περίπου 0,1 mg/ml έως περίπου 0,9 mg/ml. Ένα προτιμώμενο επιφανειακώς δραστικό μέσον είναι πολυαιθοξυλιωμένο ρετσινό-λαδο και ένας προτιμώμενος διαλύτης αραίωσης είναι γαλακτοποιημένο διάλυμα εγχύσεως του Ringer (Lactated Ringer's Injection).
CY20081100590T 2001-01-25 2008-06-05 Μεθοδοι για την παρασκευη φαρμακευτικων συνθεσεων που περιεχουν αναλογα εποθειλονης για την θεραπευτικη αγωγη του καρκινου CY1108114T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29000801P 2001-05-11 2001-05-11
EP02713446A EP1353668B1 (en) 2001-01-25 2002-01-22 Processes for the preparation of pharmaceutical preparations containing epothilone analogues for the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1108114T1 true CY1108114T1 (el) 2014-02-12

Family

ID=28678063

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100590T CY1108114T1 (el) 2001-01-25 2008-06-05 Μεθοδοι για την παρασκευη φαρμακευτικων συνθεσεων που περιεχουν αναλογα εποθειλονης για την θεραπευτικη αγωγη του καρκινου

Country Status (24)

Country Link
US (1) US6670384B2 (el)
EP (2) EP1938821B1 (el)
KR (1) KR100851719B1 (el)
CN (1) CN100341505C (el)
AR (1) AR032409A1 (el)
AT (1) ATE389401T1 (el)
BG (1) BG66494B1 (el)
BR (1) BRPI0206509B8 (el)
CY (1) CY1108114T1 (el)
CZ (1) CZ20032021A3 (el)
DE (1) DE60225666T2 (el)
DK (1) DK1353668T3 (el)
EE (1) EE05301B1 (el)
ES (1) ES2304240T3 (el)
HU (1) HU229349B1 (el)
IS (1) IS2865B (el)
NO (1) NO20130070L (el)
NZ (1) NZ526870A (el)
PE (1) PE20020734A1 (el)
PT (1) PT1353668E (el)
SK (1) SK288098B6 (el)
TW (1) TWI342211B (el)
UY (1) UY27137A1 (el)
YU (1) YU58203A (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
KR20030071853A (ko) * 2001-01-25 2003-09-06 브리스톨-마이어스스퀴브컴파니 에포틸론 유사체를 함유한 비경구용 제제
HUP0303175A2 (hu) 2001-02-20 2003-12-29 Bristol-Myers Squibb Co. Epotilonszármazékok alkalmazása makacs tumorok kezelésére alkalmas gyógyszerkészítmény előállítására
CA2440555A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
SI1767535T1 (sl) 2002-08-23 2010-03-31 Sloan Kettering Inst Cancer Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1663214A1 (en) * 2003-09-02 2006-06-07 Novartis AG Cancer treatment with epothilones
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
HRP20080349T3 (hr) * 2004-11-18 2009-01-31 Bristol-Myers Squibb Company Zrna premazana enteričkom smjesom koja sadrže iksabepilon
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CA2597647A1 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130501A2 (en) 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
WO2012170384A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
PL401116A1 (pl) * 2012-10-09 2014-04-14 Ryszka Florian Farmaceutyczny Zakład Naukowo-Produkcyjny Biochefa Kompozycja dodawana do płynów infuzyjnych
CN107041886A (zh) * 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用
EP4087545A1 (en) 2020-01-10 2022-11-16 R-Pharm US Operating LLC Compositions of ixabepilone
PL4062913T3 (pl) * 2020-09-02 2024-07-22 Beijing Biostar Pharmaceuticals Co., Ltd. Stały preparat doustny utidelonu

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
ES2178093T5 (es) 1995-11-17 2009-02-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Derivados de epotilon y su preparacion.
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
AU753546B2 (en) 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
CA2281105A1 (en) 1997-02-25 1998-09-03 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilones with a modified side chain
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
PT1001951E (pt) 1997-07-16 2003-02-28 Schering Ag Derivados de tiazolo, processo para a sua preparacao e utilizacao
IL134419A0 (en) 1997-08-09 2001-04-30 Schering Ag Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
WO1999039694A2 (en) 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
IL143069A0 (en) 1998-11-20 2002-04-21 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
EP1140944B1 (en) * 1998-12-22 2003-08-27 Novartis AG Epothilone derivatives and their use as antitumor agents
SK11852001A3 (sk) 1999-02-18 2002-04-04 Schering Aktiengesellschaft Deriváty epotiólonu, spôsoby ich výroby a ich farmaceutické použitie
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
WO2001092255A2 (en) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
US6670384B2 (en) 2003-12-30
IS6891A (is) 2003-07-24
DE60225666T2 (de) 2009-04-16
PE20020734A1 (es) 2002-08-17
US20020169190A1 (en) 2002-11-14
EP1353668A1 (en) 2003-10-22
IS2865B (is) 2014-02-15
CZ20032021A3 (cs) 2004-05-12
TWI342211B (en) 2011-05-21
ATE389401T1 (de) 2008-04-15
HUP0302726A2 (hu) 2003-11-28
AR032409A1 (es) 2003-11-05
HK1116339A1 (en) 2008-12-19
NO20130070L (no) 2003-09-04
EE05301B1 (et) 2010-06-15
HK1065946A1 (en) 2005-03-11
SK288098B6 (sk) 2013-07-02
DK1353668T3 (da) 2008-06-30
EP1938821A2 (en) 2008-07-02
DE60225666D1 (de) 2008-04-30
KR100851719B1 (ko) 2008-08-11
EP1353668B1 (en) 2008-03-19
YU58203A (sh) 2006-08-17
CN100341505C (zh) 2007-10-10
ES2304240T3 (es) 2008-10-01
SK8562003A3 (en) 2004-07-07
CN1496258A (zh) 2004-05-12
HUP0302726A3 (en) 2007-08-28
HU229349B1 (en) 2013-11-28
EE200300320A (et) 2003-10-15
PT1353668E (pt) 2008-06-30
KR20040048874A (ko) 2004-06-10
BG108112A (bg) 2004-11-30
BG66494B1 (bg) 2015-06-30
EP1938821B1 (en) 2016-03-30
UY27137A1 (es) 2002-08-30
BRPI0206509B8 (pt) 2021-05-25
EP1938821A3 (en) 2009-02-18
NZ526870A (en) 2005-11-25
BRPI0206509B1 (pt) 2018-10-02
BR0206509A (pt) 2004-09-08
BRPI0206509A8 (pt) 2017-09-19

Similar Documents

Publication Publication Date Title
CY1108114T1 (el) Μεθοδοι για την παρασκευη φαρμακευτικων συνθεσεων που περιεχουν αναλογα εποθειλονης για την θεραπευτικη αγωγη του καρκινου
BG108019A (en) Parenteral formulation containing epothilone analogs
RU2192249C2 (ru) Жидкая стабильная композиция на основе парацетамола и способ ее получения
JPH06507914A (ja) タキサン類の誘導体を基とする新規組成物
KR890701562A (ko) 면역조절 아자스 피란류
IT9048456A1 (it) Medicamenti contenenti acidi carbossilici contenenti zolfo quali agenti attivi nonche' procedimento per la loro produzione e loro impiego per la lotta ai retrovirus.
KR930003912A (ko) 울혈성 심장 마비 치료법
BR9912356A (pt) Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato
CN1525856A (zh) 含吡唑啉酮衍生物的稳定的高浓度注射剂
RU2398578C2 (ru) Фармацевтическая композиция, содержащая производное таксана, которая предназначена для приготовления инфузионного раствора, способ его приготовления и использование
NO20033341L (no) Metoder for administrering av epothilone-analoger for behandling av kreft
JP2021519817A (ja) 液体薬学的製剤
US3499088A (en) Stable aqueous solutions of coenzyme q with a polyoxyethylene hydrogenated castor oil and propylene glycol and process for the manufacture thereof
JP2006257020A (ja) 安定な高濃度エダラボン注射液
RU2002755C1 (ru) Производное целлюлозы и госсипола, обладающее интерферониндуцирующим и противовирусным действием
KR910000743A (ko) 티에노피란 유도체, 이의 제조방법 및 용도
DE69130771D1 (de) Alkylidenanaloge von 1'-aminospiro-[isochinolin-4(1h), 3'-pyrrolidin]-1,2',3,5'(2h)-tetronen, verwendbar als aldose reduktase-inhibitoren in vivo
CA2486571C (en) Pharmaceutical composition
KR101295010B1 (ko) 검은 생강으로부터 분리된 신규 화합물 및 그 화합물의 항바이러스제로서의 용도
AR029259A1 (es) Compuestos 1,1'(1,2 etendiilo) bis (benceno) sustituidos, un proceso para su preparacion composiciones farmaceuticas y el uso de dichos compuestos para preparar agentes intensificadores de la absorcion de glucosa
KR900006309A (ko) 신규 2-카르보닐 치환 n, n'-디-(트리메톡시벤조일)피페라진, 이들의 제조방법 및 이들을 함유한 치료 조성물
ES2062271T3 (es) Preparaciones farmaceuticas.
KR100466955B1 (ko) 항종양제함유조성물
ES2070959T3 (es) Utilizacion de derivados del bis(4-hidroxifeniltio)metano en el tratamiento de la diabetes mellitus.
US11376266B2 (en) Antitumor agent